Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wild-type Ad5 (Human Adenovirus Serotype 5) is a non-enveloped, double-stranded DNA virus that naturally infects human respiratory epithelial cells. It enters host cells primarily through high-affinity binding of its fiber knob domain to the Coxsackievirus and Adenovirus Receptor (CAR), followed by internalization via alpha-v integrins. In biomedical research and oncology, wild-type Ad5 serves as the foundational parental strain for many engineered oncolytic viruses and gene therapy vectors. While it possesses potent natural lytic capabilities, its use as a systemic therapeutic is hindered by significant liver sequestration (mediated by blood factor binding) and high levels of pre-existing neutralizing antibodies in the general population. Consequently, it is most frequently used in clinical and preclinical studies as a benchmark or control to evaluate the improved safety, targeting, and efficacy profiles of next-generation, genetically modified adenoviral agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human adenovirus serotype 5.